Skip to content

Perspective Chapter: Ketamine, Depression, and Gender Bias

Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed, Anfal F. Bin Dayel, Asma S. Alonazi, Jawza F. Al Sabhan, Musaad A. Alshammari

Ketamine Revisited - New Insights into NMDA Inhibitors September 14, 2022 DOI: 10.5772/intechopen.103656 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Depression Esketamine Ketamine
Key findings Sexual dimorphism is an important but understudied factor in depression research, and considering sex in preclinical studies is vital for understanding ketamine's antidepressant effects and treatment resistance mechanisms.

Abstract

Our knowledge regarding pathological and treatment resistance mechanisms involved in depression is far from understood. Sexual dimorphism in this topic is well acknowledged. However, the need to highlight sex-based discrepancies is unmet. Ketamine, the dissociative anesthetic, has emerged as a rapid antidepressant. This chapter reviewed sexual dimorphism in pharmacological and genetic models of depression, emphasizing ketamine-related antidepressant effects. Aiming by this report, we would extend our knowledge, highlight gender as one of the vital factors in examining depression in preclinical studies, and elucidate complex antidepressant effects associated with ketamine administration. Our central goal is to encourage neuroscientists to consider gender in their studies of mood disorders.

Comparable studies

Other narrative reviews on ketamine for depression, most cited first.

Explore topics

By condition and practice